HopeStage
Back to all studies
CompletedNCT01933919

Fluvoxamine Compared With Placebo for OCD in Young People

About this title

A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder

Read the official source — NCT01933919
Medication studyAges 6–18
The study in practice

Understand this study

Who was this study for?

This study was for people with OCD. Listed age limits: 6 years to 18 years. Other eligibility criteria applied.

Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: August 14, 2013
Recruitment status
Completed
Enrollment listed in the registry
38
Sponsor
AbbVie
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Not clearly listed
Age range
From 6 Years to 18 Years
Official registry ID
NCT01933919
Official title
Show the full official title

A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AbbVie.

Did this study involve medication?

Yes. The study involved medication, including Fluvoxamine maleate and Placebo.

Who was this study for?

This study was for people with OCD. Listed age limits: 6 years to 18 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies